Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 5/20 | 0.42 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.40 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5569099 | 0.83 | CARM1 (0.50) | CCR3LMNAMAPTNPSR1 | |
| SCHEMBL5568467 | 0.76 | CARM1 (0.50) | CCR3LMNA | |
| SCHEMBL5570341 | 0.73 | CARM1 (0.50) | LMNAMAPTNPSR1 | |
| SCHEMBL5563471 | 0.72 | MAPT (0.48) | CCR3ALDH1A1LMNAMAPTNPSR1 | |
| SCHEMBL5565616 | 0.71 | CARM1 (0.56) | ALDH1A1LMNAMAPTNPSR1SMN1; SMN2 | |
| SCHEMBL4863197 | 0.69 | TP53 (0.50) | LMNAMAPTSMN1; SMN2 | |
| SCHEMBL5568492 | 0.68 | CARM1 (0.52) | CCR3 | |
| SCHEMBL4871029 | 0.68 | TP53 (0.55) | TSHRALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL6300836 | 0.68 | CARM1 (0.51) | CCR3ALDH1A1LMNAMAPTNPSR1 | |
| SCHEMBL5567777 | 0.68 | CARM1 (0.48) | CCR3LMNAMAPTNPSR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903103-B2 | Linear cyclic ureas | LES LABORATORIES SERVIER (FR) | 2005-06-07 | — | — | US | disclosed |
| US-20030229100-A1 | New linear cyclic ureas | PEGLION JEAN-LOUIS (FR) | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229100-A1 | New linear cyclic ureas | GUCY1B1, UACA, GUCY1A1 | LTA4H 2598/4885CCR3 975/4885TSHR 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.